Mechanisms of 5HT2A Receptor Desensitization

5HT2A受体脱敏机制

基本信息

  • 批准号:
    6916264
  • 负责人:
  • 金额:
    $ 23.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-01 至 2007-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term goals of our studies are to identify the molecular mechanisms of desensitization of serotonin 2A (5-HT2A) receptor signaling. Adaptive changes in post-synaptic 5-HT2A receptor signaling underlie the mechanism of action of several drug treatments for psychiatric disorders including anxiety, schizophrenia, depression, and bipolar disorder. Paradoxically, chronic treatment with both 5-HT2A receptor agonist such as DOI and antagonists including olanzapine desensitize 5-HT2a receptor signaling. Atypical antipsychotics are 5-HT2A receptor antagonists. Although these drugs are widely used, significant numbers of individuals are refractory to drug therapy and their effectiveness is delayed about 2 weeks after treatment is initiated. To help to resolve these problems, we plan to investigate the mechanisms by which 5-HT2A receptor signaling is desensitized. We will examine the mechanisms of desensitization of 5-HT2A receptor signaling induced with 5-HT2A receptor agonists (Aim 1), 5-HT2a receptor antagonists (Aim 2) and regulators of G protein signaling (RGS) proteins (Aim 3) in cells in culture and in vivo. Our hypothesis is that Jak/Stat signaling is critical for antagonist-induced desensitization, while the receptor-G protein functioning is reduced in agonist-induced desensitization of 5-HT2.A receptor signaling. We will test the hypothesis that RGS proteins also cause adaptive changes leading to 5-HT2A receptor desensitization via mechanisms in addition to acting as GTPase-activating proteins (GAPs). Neuroendocrine responses to 5-HT2A receptor-stimulation will be used as an index of desensitization of 5-HT2A receptor signaling in vivo. A major advantage of the neuroendocrine challenge tests is that the results obtained in experimental animals can be rapidly applied to humans since these tests can be performed in humans. Ultimately the purpose of these studies is to identify new targets for therapeutic intervention for psychiatric disorders currently treated with drugs that alter 5-HT2A receptor signaling. By understanding the mechanisms involved in neuroadaptation, new approaches can be developed to reduce the delay in therapeutic response and treat individuals refractory to current therapies
描述(由申请人提供):我们研究的长期目标是确定5-羟色胺2A(5-HT 2A)受体信号转导脱敏的分子机制。突触后5-HT 2A受体信号传导的适应性变化是几种药物治疗精神障碍(包括焦虑症、精神分裂症、抑郁症和双相情感障碍)的作用机制的基础。奇怪的是,用5-HT 2a受体激动剂如DOI和拮抗剂包括奥氮平的长期治疗使5-HT 2a受体信号传导脱敏。非典型抗精神病药是5-HT 2A受体拮抗剂。虽然这些药物被广泛使用,但大量个体对药物治疗是难治的,并且它们的有效性在治疗开始后延迟约2周。为了帮助解决这些问题,我们计划研究5-HT 2A受体信号传导脱敏的机制。我们将研究5-HT 2A受体激动剂(Aim 1)、5-HT 2a受体拮抗剂(Aim 2)和G蛋白信号传导调节剂(RGS)蛋白(Aim 3)在培养和体内细胞中诱导的5-HT 2A受体信号传导脱敏的机制。我们的假设是,Jak/Stat信号传导对于拮抗剂诱导的脱敏是至关重要的,而受体-G蛋白功能在激动剂诱导的5-HT 2.A受体信号传导的脱敏中降低。我们将测试的假设,RGS蛋白也引起适应性变化,导致5-HT 2A受体脱敏通过机制,除了作为GTP酶激活蛋白(GAP)。对5-HT 2A受体刺激的神经内分泌反应将被用作体内5-HT 2A受体信号传导脱敏的指标。神经内分泌激发试验的一个主要优点是,在实验动物中获得的结果可以迅速应用于人类,因为这些试验可以在人类中进行。这些研究的最终目的是确定目前用改变5-HT 2A受体信号的药物治疗的精神疾病的治疗干预的新靶点。通过了解神经适应的机制,可以开发新的方法来减少治疗反应的延迟,并治疗对当前疗法无效的个体

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nancy A Muma其他文献

Nancy A Muma的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nancy A Muma', 18)}}的其他基金

HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD
HTS 鉴定小分子以破坏 HD 中异常的亨廷顿蛋白相互作用
  • 批准号:
    8886806
  • 财政年份:
    2015
  • 资助金额:
    $ 23.68万
  • 项目类别:
HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD
HTS 鉴定小分子以破坏 HD 中异常的亨廷顿蛋白相互作用
  • 批准号:
    8997127
  • 财政年份:
    2015
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    7586795
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    8250832
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    6674600
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    7058231
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    6760864
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    7407917
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    7462079
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
Mechanisms of 5HT2A Receptor Desensitization
5HT2A受体脱敏机制
  • 批准号:
    7799762
  • 财政年份:
    2003
  • 资助金额:
    $ 23.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了